Oscotec Inc. (KOSDAQ:039200)

Market Cap	1.49T +15.5%
Revenue (ttm)	101.55B +191.1%
Net Income	55.56B +14,328.1%
EPS	1,452.76
Shares Out	38.26M
PE Ratio	26.74
Forward PE	46.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,363
Open	39,300
Previous Close	38,100
Day's Range	37,500 - 40,000
52-Week Range	27,300 - 66,000
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Oscotec

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Employees: 55
• Stock Exchange: KOSDAQ
• Ticker Symbol: 039200

Financial Performance

In 2025, Oscotec's revenue was 99.84 billion, an increase of 193.58% compared to the previous year's 34.01 billion. Earnings were 52.34 billion, an increase of 5871.65%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error